BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President
January 09, 2024 08:30 ET
|
BioCorRx Inc
ANAHEIM, CA, Jan. 09, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and...
BioCorRx Submits Fast Track Application to FDA for BICX104, an Implantable Biodegradable Naltrexone Pellet for The Treatment of Opioid Use Disorder
July 18, 2023 08:30 ET
|
BioCorRx Inc
ANAHEIM, CA, July 18, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and...
BioCorRx Provides Business Update for the First Quarter of 2023
May 16, 2023 08:30 ET
|
BioCorRx Inc
Revenue Increases 97% ANAHEIM, CA, May 16, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for...
BioCorRx Attended 4th Annual NIH HEAL Initiative Investigator Meeting; Shares Update on BICX104 Data
February 23, 2023 08:30 ET
|
BioCorRx Inc
ANAHEIM, CA, Feb. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance use and related...
BioCorRx Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
January 19, 2023 08:30 ET
|
BioCorRx Inc
ANAHEIM, CA, Jan. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance use and related...
BioCorRx Provides Business Update for the Second Quarter of 2022
August 16, 2022 08:30 ET
|
BioCorRx Inc
ANAHEIM, CA, Aug. 16, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and...
BioCorRx Provides Business Update for the Third Quarter of 2020; BioCorRx Subsidiary, BioCorRx Pharmaceuticals Inc. Progressing with Pivotal Nonclinical BICX102 Study
November 16, 2020 08:30 ET
|
BioCorRx, Inc.
Announces Promotion of Lourdes Felix to CEO; Brady Granier to Serve as President ANAHEIM, CA, Nov. 16, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire ‒ BioCorRx Inc. (OTCQB: BICX) (the “Company”), a...
BioCorRx Announces Capital Restructuring and Provides Business Update
October 07, 2019 08:30 ET
|
BioCorRx, Inc.
ANAHEIM, CA, Oct. 07, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use...
BioCorRx Inc. Unveils New UnCraveRx™ Weight Loss Program; Appoints Notable Dr. Kenneth Orbeck as Medical Director
May 01, 2019 08:30 ET
|
BioCorRx Inc
ANAHEIM, CA, May 01, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a leader, developer and provider of advanced solutions in the treatment of addiction...
BioCorRx Awarded NIDA Grant of Approximately $5.7 Million for BICX102, a Sustained Release Naltrexone Implant for the Treatment of Opioid Use Disorder
January 22, 2019 07:30 ET
|
BioCorRx Inc
ANAHEIM, CA, Jan. 22, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use...